Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Disease
- HIV / AIDs
- Vaccine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 178197
License Grant
The U.S. Licensor and Owner in Ireland hereby jointly grant to Licensee the exclusive world rights to all present and future Patent Rights, Know-How and the Background Technology for all uses thereunder with the right to sublicense, to make, have made, use and sell the Products and Combination Products, and to practice, modify and improve the Licensed Processes within the Field of Activity, in the Territory.
The amendments modify method and terms of the licensing fee.
License Property
Owner has developed a non-HIV based Anti-Serum which is capable of binding the HIV virus and removing it from the bloodstream. The U.S. patents pending are 08/007,128 and 07/734,567. There are patents/pending patents in various other countries.
Field of Use
'FIELD OF ACTIVITY' shall mean the use (including any use in connection with research, development, demonstration, testing or experimentation) of the Products for, or the manufacture, sale or other disposition of the Products for, human or animal therapeutic or prophylactic use within the Territory, including without limitation, any use for arrest and therapy of, or for vaccination against, retroviruses and bacterial infections.
IPSCIO Record ID: 178198
License Grant
U.S. Licensor and Owner in Ireland hereby jointly grant to Licensee the exclusive world rights to all present and future Patent Rights, Know-How and the Background Technology for all uses thereunder with the right to sublicense, to make, have made, use and sell the Products and Combination Products, and to practice, modifyand improve the Licensed Processes within the Field of Activity, in the Territory, and to sublicense others to do the same, all as herein provided.
License Property
Licensor has been assigned Owners rights in the Patent Rights and Know-How relating to the treatment of human/animal immunodeficiency as disclosed in U.S. Patent No. 4,956,355 entitled Agents for the Arrest and Therapy of Retrieval Infections, the said assignment allows Licensor sufficient portion of rights to grant licenses to make, use, exercise and vend the Products and Licensed Processes and Licensor has been granted an Investigational New Drug (IND) status from the U.S. Food and Drug Authority for the use of the technology outlined in the U.S. Patent No. 4,956,355 in the treatment of HIV infection, IND No. 31,980.
ANTI-VIRAL FORMULATION OF DEHYDROEPIANDROSTERONE (DHEA)'s s anti-retroviral effectiveness was shown through experiments which demonstrated in tissue culture that DHEA inhibited HIV replication.
Field of Use
This agreement has application in the medical and pharmaceutical and veterinary industries.
IPSCIO Record ID: 275977
License Grant
The Licensor and Licensee of Denmark are working and cooperating with each other to conduct a joint program for the discovery and development of a vaccine.
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants the Licensee of Denmark a worldwide, nonexclusive, non sublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensor under the Research and Development Program.
Licensor grants a worldwide, non-exclusive and nontransferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor. Patent Rights and the Joint Patent Rights, to make, have made, use, sell, offer for sale and import Licensee-Combined Vaccines or the Program Vaccines.
License Property
The licensed property includes proprietary Modified Vaccinia Ankara MVA technology to design vaccines. Also developed vaccine products including those based on viral vectors, and T-cell epitope.
Field of Use
The Field shall mean any use of a vaccine product for the treatment or prevention of HIV in humans.
IPSCIO Record ID: 273437
License Grant
The Licensor of Denmark and the Licensee are working and cooperating with each other to conduct a joint program for the discovery and development of a vaccine.
The Research and Development Program will involve the systematic design and development of the Program Vaccine for use in the Field. The scope and goals of the Research and Development Program are subject to modification.
Licensor grants a worldwide, nonexclusive, nonsublicensable and nontransferable license during the Research Term to practice the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, solely in connection with activities to be performed by Licensee under the Research and Development Program.
Subject to the exercise by Licensee of the Combination Option or Option, Licensor grants to a worldwide, non-exclusive and non-transferable license, with rights to sublicense, under the Licensor Background Technology, the Licensor Patent Rights and the Joint Patent Rights, to use, sell, offer for sale and import Combined Vaccine or the Program Vaccine during the Term.
License Property
The licensed property includes proprietary Modified Vaccinia Ankara MVA technology to design vaccines. Also developed vaccine products including those based on viral vectors, and T-cell epitope.
Field of Use
The Field shall mean any use of a vaccine product for the treatment or prevention of HIV in humans.
IPSCIO Record ID: 275801
License Grant
Licensor grants sublicense rights to the Patent Rights, granted to Licensor in the Amended and Restated Exclusive License Agreement, under said rights to make, have made, use, manufacture and sell products using the Joint Patent Filing technology.
License Property
Licensor has been granted worldwide exclusive license to the Joint Patent Filing, which includes the 03-24 Technology and 03-111 Technology.
Licensed Product shall mean any HIV vaccine product other than the HIV Vaccine that cannot be developed, manufactured, used, or sold without infringing one or more Valid Claim under the Patent Rights.
The patents are titled Polyvalent, Primary HIV -1 Envelope Glycoprotein DNA Vaccine, and, Polyvalent DNA and Protein Vaccines.
This technology is a DNA-based HIV vaccine that incorporates the 03-24 Technology and the 03-111 Technology. Invention disclosure number 03-24 is entitled Primary and Polyvalent IIlV-1 Envelope Glycoprotein DNA Vaccines. And HIV protein boost technology invention is referred to as 03-111.
New Vaccine shall mean any HIV vaccine other than the HIV Vaccine.
Field of Use
The Field shall mean all HIV vaccines.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
